Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews' Q3 Revenues Fall, Net Loss Climbs

NEW YORK (GenomeWeb News) - GeneNews today said third-quarter revenues tumbled as R&D spending was stable and net loss swelled 43 percent.
Total receipts for the three months ended Sept. 30 decreased to CA$189,000 (US$204,000) from CA$878,000 year over year.
The Toronto-based company said the only source of its revenue in 2007 so far stems from a CA$2 million agreement with an Asian biomedical consortium to identify and validate biomarkers for prostate disease. The company’s 2006 revenue came from a collaboration with Pfizer, which ran its course in the first quarter of 2007. 
R&D spending was flat at around CA$2.3 million.
Net loss increased to CA$3 million from CA$2.1 million in the year-ago period.
GeneNews said it had around CA$13 million in cash and cash equivalents as of Sept. 30.
The company, which is focused on biomarker research and development for diagnostic products, did not offer revenue projections for the full year.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.